Clinical multidrug resistance in cancer: A multifactorial problem

M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States))

European Journal of Cancer

June 1, 1996

10.1016/0959-8049(96)00069-x

Cited by 178

Related Papers

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

|Clinical Cancer Research|2015|799

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

|PubMed|1996|388

High seroprevalence of Epstein–Barr virus in children with multiple sclerosis

|Neurology|2006|225

Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients

|Annals of Oncology|2003|106

Synergistic inhibition by verapamil and quinine of P-glycoprotein- mediated multidrug resistance in a human myeloma cell line model

|Blood|1991|85